Previously submitted to: JMIR Medical Informatics (no longer under consideration since Nov 29, 2022)
Date Submitted: Nov 17, 2022
Open Peer Review Period: Nov 14, 2022 - Nov 29, 2022
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Experimental validation and identify the characteristics of chromatin modulator and potential candidate drugs for sepsis
ABSTRACT
Background:
Sepsis is a common acute and critical disease, which is a systemic inflammatory response syndrome. More and more evidence shows that chromium regulators (CRs) are involved in the progress of inflammation and sepsis.
Objective:
The purpose of this study was to explore the role of CRS in sepsis patients and provide prognostic value
Methods:
CRs were obtained from previous top level studies. We downloaded four microarrays（GSE11755、GSE12624、GSE28750、GSE48080）from Gene Expression Omnibus (GEO). CRs related genes were extracted for differential analysis, and GO, KEGG, DO analysis was conducted for different CRs. We conduct PPI analysis on different CRs and screen hub genes. We use the ssGSEA algorithm to obtain the relevant immune cells and immune function infiltration matrix, and draw the relevant heat map for correlation analysis and difference analysis between immune cells and immune function. We analyzed the correlation between hub genes, immune cells and immune functions, and screened out the most relevant hub genes (IHGs). Finally, IHGs are used to build models, and nomograms, ROC curves, and calibration charts are drawn to predict IHGs related drugs and related miRNAs and genes, and RT-PCR is used to verify related genes.
Results:
We obtained 69 normal blood samples and 106 sepsis patients' blood samples, and extracted relevant CRS genes. GO analysis shows that CRS gene involves histone modification, peptidyl−lysine modification、chromatin remodeling, etc. KEGG analysis involves cell cycle, Viral carcinogenesis and Hepatocellular carcinoma signal pathways. We identified 10 hub genes, including TP53, EZH2, RNF2, and mapped relevant maps. 10 drugs such as PHA may be useful for the treatment of Sepsis. MiRNAs such as hsa-miR-4281, hsa-miR-4715-5p, hsa-miR-409-5p and TP53, CHD3, CBX4 genes are associated with this disease. RT-PCR results showed that the expression levels of TP53 and CHD3 were significantly reduced, and the expression levels of CBX4 were significantly increased
Conclusions:
Our study provides new insights into the role of CRS in sepsis, and provides reliable biomarkers to determine the prognosis of sepsis patients.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.